Recently, an international academic journal [Frontiers in Molecular Biosciences] with an impact factor of 5.246 published a medical paper titled 'Methylation of SDC2/TFPI2 and Its Diagnostic Value in Colorectal Tumorous Lesions' based on Aichangkang products.

中文名：《SDC2/TFPI2甲基化在结直肠肿瘤病变中的诊断价值》

This paper has attracted the attention of many tumor detection researchers. The paper compares the differences between dual-target fecal DNA detection and other detection methods in detail, and once again proves that among many fecal DNA early screening methods for colorectal cancer, compared with the traditional SDC2 single-target The detection method, Aichangkang® dual-target fecal DNA tumor detection technology has higher indicators in terms of sensitivity and specificity, and can also detect colorectal precancerous lesions earlier.

Colorectal cancer (CRC) affects millions of people around the world. It is unique in that it progresses slowly, making it preventable and often curable, and early detection can significantly reduce mortality. Colonoscopy plus pathological testing is the gold standard for colorectal cancer diagnosis, but its adherence in average-risk populations is low due to the invasiveness and complexity of the bowel preparation process.

Traditional detection methods, fecal occult blood test (FOBT) and fecal immunochemical test (FIT), are noninvasive, but their sensitivity is insufficient, especially for stage I colorectal cancer and advanced adenomas.

Aberrant DNA methylation can occur at a very early stage, and to date, several colorectal cancer methylation biomarkers have been identified, including SDC2, NDRG4, BMP3, VIM, SFRP2, and SEPT9, but single markers The sensitivity is usually less than 90%. SDC2 has been identified as a potential biomarker for colorectal cancer. Aberrant methylation in SDC2 CpG islands has been found in tissue, blood, and feces.

A study based on Chinese stool samples showed that the sensitivity and specificity of SDC2 for colorectal cancer were 81.1% and 93.3%, respectively. Korean researchers used the LTE-q methylation-specific PCR (MSP) method to enrich SDC2, which requires two rounds of PCR, that is, first unidirectional linear amplification of the target DNA, and then MSP analysis of the target region, which is useful for The detection sensitivity of colorectal cancer was 90.0% and the specificity was 90.9%.

New method: dual target detection with better performance

Figure 1 shows a comparison of the sensitivity of different assays (SDC2 alone, TFPI2 alone, and SDC2/TFPI2 combination) in different parts of the colorectum.

Figure 1. Comparison of the sensitivity of SDC2, TFPI2, and SDC2/TFPI2 to detect colorectal cancer at different sites.

The blue line represents the detection sensitivity of SDC2, the red line represents the detection sensitivity of TFPI2, and the green line represents the combined detection sensitivity of SDC2/TFPI2.

Data result:

Based on the above four datasets, it was found that the sensitivity of SDC2/TFPI2 combined detection was significantly higher than that of SDC2 single gene detection. TFPI2 can improve the detection sensitivity of SDC2, especially for left colon cancer, rectal cancer and sigmoid colon cancer. Tissue samples and stool samples showed the same trend.

Experimental results:

Compared with the single-target SDC2 detection method, Aichangkang® dual-target SDC2+TFPI2 combined detection has more advantages.

New discovery: dual-target detection can better detect early-stage adenomas

Using colonoscopy as the gold standard and MSP results as the evaluation index, the diagnostic performance of SDC2, TFPI2 and SDC2/TFPI2 in stool samples was evaluated by ROC curve analysis (Figure 2 and Table 1). Figure 2 (A-C) is the ROC curve based on the Ct value, and Figure 2 (D-F) is the ROC curve based on the ML value.

Figure 2. Diagnostic performance of methylation-specific PCR targeting SDC2, TFPI2, and SDC2/TFPI2 in stool samples.

Table 1. Diagnostic performance of methylation-specific PCR in stool samples using Ct value and ML as indicators

Data result:

Ct-based ROC analysis (Fig. 2(A) and Table 1) showed that the AUC value of SDC2/TFPI2 to differentiate colorectal cancer vs adenoma group was 0.72, which was lower than that of colorectal cancer vs normal group and adenoma vs normal group.

Experimental results:

Aichangkang® dual-target SDC2+TFPI2 combined detection can better detect early-stage adenomas.

In recent years, Emerson Life Technology has developed a series of products in the field of early diagnosis of multiple high-incidence malignant tumors, covering digestive system tumors (intestinal cancer, gastric cancer, liver cancer, esophageal cancer, pancreatic cancer), gynecological tumors (cervical cancer, endometrial cancer) cancer), urinary system tumors (bladder cancer), pan-cancer species, etc.

With outstanding product performance, Amisen Life Technology has won four rounds of financing of hundreds of millions of yuan and strong support from governments at all levels, and has won various honorary titles.

Behind the excellent clinical performance indicators and technology platform is the unswerving benevolence of doctors, escorting the life and health of the public is the persistent pursuit of Emerson Life Technology!

Early tumor screening to fight cancer

Emerson Life Technology, keep moving forward!

About Emerson Life Technology

Emerson Life Technology focuses on the early diagnosis and screening of high-incidence malignant tumors, providing digestive system tumors (intestinal cancer, gastric cancer, liver cancer, esophageal cancer, pancreatic cancer), gynecological tumors (cervical cancer, endometrial cancer), urinary system tumors (bladder cancer) Cancer), pan-cancer species and other high-incidence malignant tumor genetic testing services.

The company has been based on local development for many years, and its core technology is independent and controllable. After several years of accumulation, a diversified product detection system with methylation navigation technology as the core has been established; after tens of thousands of clinical sample verifications, the screening sensitivity and specificity have reached the industry-leading level! The company has applied for 55 patents and published more than 10 cutting-edge research results. It has become one of the few multi-type cancer screening service providers in the world and a tumor early diagnosis and early screening enterprise that licenses external technology license-out.